CJC-1295 testing round-up: what our latest samples measured
8 independently tested samples across 7 companies, and what the results say about CJC-1295.
The Peptide Institute Testing Desk··5 min read
CJC-1295 is a growth-hormone-releasing hormone analog with a development status of "preclinical / early human studies". The Institute rates the strength of its published evidence as emerging. A GHRH analog engineered for extended half-life, studied for its ability to raise growth hormone and IGF-1 levels.
This report covers the CJC-1295 samples processed in our most recent testing cycle. Every specimen was purchased anonymously at retail, transferred under chain-of-custody documentation, and analysed by an independent contract laboratory.
The Institute has independently tested 8 CJC-1295 samples from 7 companies. 100% met their label claims on purity and content. Measured purity ranged from 96.7% to 99.1%, averaging 97.9%. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
23 samples, 12 sellers, one compound with almost no human evidence behind it. Measured purity ranged from 61% to 98.9%.
Institute Investigation
Free download
Get the free Peptide Playbook, plus new breakthroughs as they happen.
What peptides are, why people are using them, and what results people are talking about,
in plain English. Sign up and we email you the Playbook right away.
